nodes	percent_of_prediction	percent_of_DWPC	metapath
Norethindrone—ABCB1—Mitomycin—urinary bladder cancer	0.163	0.271	CbGbCtD
Norethindrone—ALB—Fluorouracil—urinary bladder cancer	0.0767	0.128	CbGbCtD
Norethindrone—CYP3A4—Thiotepa—urinary bladder cancer	0.074	0.123	CbGbCtD
Norethindrone—CYP3A5—Etoposide—urinary bladder cancer	0.0514	0.0857	CbGbCtD
Norethindrone—ABCB1—Gemcitabine—urinary bladder cancer	0.0469	0.0781	CbGbCtD
Norethindrone—ALB—Methotrexate—urinary bladder cancer	0.0423	0.0704	CbGbCtD
Norethindrone—ABCB1—Cisplatin—urinary bladder cancer	0.0341	0.0567	CbGbCtD
Norethindrone—ABCB1—Etoposide—urinary bladder cancer	0.0335	0.0558	CbGbCtD
Norethindrone—ABCB1—Doxorubicin—urinary bladder cancer	0.0228	0.038	CbGbCtD
Norethindrone—ABCB1—Methotrexate—urinary bladder cancer	0.0221	0.0368	CbGbCtD
Norethindrone—CYP3A4—Etoposide—urinary bladder cancer	0.0201	0.0334	CbGbCtD
Norethindrone—CYP3A4—Doxorubicin—urinary bladder cancer	0.0137	0.0228	CbGbCtD
Norethindrone—CYP2C19—urine—urinary bladder cancer	0.00442	0.153	CbGeAlD
Norethindrone—CYP3A4—urine—urinary bladder cancer	0.00261	0.0905	CbGeAlD
Norethindrone—SHBG—prostate gland—urinary bladder cancer	0.00239	0.0827	CbGeAlD
Norethindrone—PGR—prostate gland—urinary bladder cancer	0.00215	0.0745	CbGeAlD
Norethindrone—Quinestrol—ESR1—urinary bladder cancer	0.00173	0.124	CrCbGaD
Norethindrone—PGR—epithelium—urinary bladder cancer	0.00158	0.0547	CbGeAlD
Norethindrone—PGR—smooth muscle tissue—urinary bladder cancer	0.00152	0.0527	CbGeAlD
Norethindrone—Ethynodiol—ESR1—urinary bladder cancer	0.00142	0.102	CrCbGaD
Norethindrone—Allylestrenol—ESR1—urinary bladder cancer	0.00134	0.0966	CrCbGaD
Norethindrone—Mestranol—ESR1—urinary bladder cancer	0.00131	0.0941	CrCbGaD
Norethindrone—SHBG—female reproductive system—urinary bladder cancer	0.0013	0.0451	CbGeAlD
Norethindrone—Desogestrel—ESR1—urinary bladder cancer	0.00129	0.0929	CrCbGaD
Norethindrone—CYP3A5—prostate gland—urinary bladder cancer	0.00125	0.0433	CbGeAlD
Norethindrone—Norgestimate—ESR1—urinary bladder cancer	0.00121	0.0869	CrCbGaD
Norethindrone—SHBG—vagina—urinary bladder cancer	0.00118	0.0408	CbGeAlD
Norethindrone—PGR—female reproductive system—urinary bladder cancer	0.00117	0.0407	CbGeAlD
Norethindrone—PGR—vagina—urinary bladder cancer	0.00106	0.0368	CbGeAlD
Norethindrone—Etonogestrel—ESR1—urinary bladder cancer	0.00105	0.0752	CrCbGaD
Norethindrone—Ethinyl Estradiol—ESR2—urinary bladder cancer	0.00101	0.0728	CrCbGaD
Norethindrone—CYP3A5—renal system—urinary bladder cancer	0.000852	0.0295	CbGeAlD
Norethindrone—CYP2C19—vagina—urinary bladder cancer	0.000784	0.0271	CbGeAlD
Norethindrone—Acute coronary syndrome—Cisplatin—urinary bladder cancer	0.000773	0.00307	CcSEcCtD
Norethindrone—Renal failure—Cisplatin—urinary bladder cancer	0.000771	0.00306	CcSEcCtD
Norethindrone—Pulmonary embolism—Methotrexate—urinary bladder cancer	0.000769	0.00305	CcSEcCtD
Norethindrone—Myocardial infarction—Cisplatin—urinary bladder cancer	0.000769	0.00305	CcSEcCtD
Norethindrone—Tension—Thiotepa—urinary bladder cancer	0.000767	0.00304	CcSEcCtD
Norethindrone—Breast pain—Doxorubicin—urinary bladder cancer	0.000763	0.00303	CcSEcCtD
Norethindrone—Nervousness—Thiotepa—urinary bladder cancer	0.000759	0.00301	CcSEcCtD
Norethindrone—Haemoglobin—Gemcitabine—urinary bladder cancer	0.000759	0.00301	CcSEcCtD
Norethindrone—Amenorrhoea—Doxorubicin—urinary bladder cancer	0.000758	0.00301	CcSEcCtD
Norethindrone—Jaundice cholestatic—Doxorubicin—urinary bladder cancer	0.000758	0.00301	CcSEcCtD
Norethindrone—Haemorrhage—Gemcitabine—urinary bladder cancer	0.000755	0.003	CcSEcCtD
Norethindrone—Nausea—Mitomycin—urinary bladder cancer	0.000753	0.00299	CcSEcCtD
Norethindrone—Haemoglobin—Fluorouracil—urinary bladder cancer	0.000746	0.00296	CcSEcCtD
Norethindrone—Haemorrhage—Fluorouracil—urinary bladder cancer	0.000743	0.00295	CcSEcCtD
Norethindrone—Connective tissue disorder—Gemcitabine—urinary bladder cancer	0.000742	0.00295	CcSEcCtD
Norethindrone—Hepatobiliary disease—Cisplatin—urinary bladder cancer	0.000742	0.00294	CcSEcCtD
Norethindrone—Levonorgestrel—ESR1—urinary bladder cancer	0.00074	0.0532	CrCbGaD
Norethindrone—Pulmonary embolism—Epirubicin—urinary bladder cancer	0.00072	0.00286	CcSEcCtD
Norethindrone—Erythema multiforme—Gemcitabine—urinary bladder cancer	0.000714	0.00283	CcSEcCtD
Norethindrone—Acute coronary syndrome—Etoposide—urinary bladder cancer	0.000708	0.00281	CcSEcCtD
Norethindrone—Renal failure—Etoposide—urinary bladder cancer	0.000706	0.0028	CcSEcCtD
Norethindrone—Fluoxymesterone—ESR1—urinary bladder cancer	0.000705	0.0507	CrCbGaD
Norethindrone—Myocardial infarction—Etoposide—urinary bladder cancer	0.000704	0.00279	CcSEcCtD
Norethindrone—Connective tissue disorder—Cisplatin—urinary bladder cancer	0.000692	0.00275	CcSEcCtD
Norethindrone—PGR—lymph node—urinary bladder cancer	0.000687	0.0238	CbGeAlD
Norethindrone—Immune system disorder—Gemcitabine—urinary bladder cancer	0.000682	0.00271	CcSEcCtD
Norethindrone—Hepatobiliary disease—Etoposide—urinary bladder cancer	0.000679	0.0027	CcSEcCtD
Norethindrone—Convulsion—Thiotepa—urinary bladder cancer	0.000677	0.00269	CcSEcCtD
Norethindrone—Danazol—ESR1—urinary bladder cancer	0.000674	0.0485	CrCbGaD
Norethindrone—Alopecia—Gemcitabine—urinary bladder cancer	0.000667	0.00265	CcSEcCtD
Norethindrone—Pulmonary embolism—Doxorubicin—urinary bladder cancer	0.000666	0.00264	CcSEcCtD
Norethindrone—ABCB1—prostate gland—urinary bladder cancer	0.000664	0.023	CbGeAlD
Norethindrone—Unspecified disorder of skin and subcutaneous tissue—Thiotepa—urinary bladder cancer	0.000661	0.00262	CcSEcCtD
Norethindrone—Alopecia—Fluorouracil—urinary bladder cancer	0.000656	0.0026	CcSEcCtD
Norethindrone—Thrombophlebitis—Methotrexate—urinary bladder cancer	0.000645	0.00256	CcSEcCtD
Norethindrone—CYP3A4—renal system—urinary bladder cancer	0.00064	0.0222	CbGeAlD
Norethindrone—Photosensitivity—Methotrexate—urinary bladder cancer	0.000636	0.00252	CcSEcCtD
Norethindrone—Immune system disorder—Cisplatin—urinary bladder cancer	0.000636	0.00252	CcSEcCtD
Norethindrone—ALB—lymph node—urinary bladder cancer	0.00063	0.0218	CbGeAlD
Norethindrone—Ethinyl Estradiol—ESR1—urinary bladder cancer	0.000623	0.0449	CrCbGaD
Norethindrone—Alopecia—Cisplatin—urinary bladder cancer	0.000622	0.00247	CcSEcCtD
Norethindrone—Skin disorder—Thiotepa—urinary bladder cancer	0.00062	0.00246	CcSEcCtD
Norethindrone—CYP3A5—vagina—urinary bladder cancer	0.000617	0.0214	CbGeAlD
Norethindrone—Erythema multiforme—Etoposide—urinary bladder cancer	0.00061	0.00242	CcSEcCtD
Norethindrone—Flatulence—Cisplatin—urinary bladder cancer	0.000604	0.0024	CcSEcCtD
Norethindrone—Thrombophlebitis—Epirubicin—urinary bladder cancer	0.000604	0.0024	CcSEcCtD
Norethindrone—Photosensitivity—Epirubicin—urinary bladder cancer	0.000595	0.00236	CcSEcCtD
Norethindrone—Immune system disorder—Etoposide—urinary bladder cancer	0.000583	0.00231	CcSEcCtD
Norethindrone—Anaphylactoid reaction—Methotrexate—urinary bladder cancer	0.000577	0.00229	CcSEcCtD
Norethindrone—Alopecia—Etoposide—urinary bladder cancer	0.00057	0.00226	CcSEcCtD
Norethindrone—Somnolence—Thiotepa—urinary bladder cancer	0.000567	0.00225	CcSEcCtD
Norethindrone—ABCB1—seminal vesicle—urinary bladder cancer	0.000562	0.0195	CbGeAlD
Norethindrone—Dyspepsia—Thiotepa—urinary bladder cancer	0.000562	0.00223	CcSEcCtD
Norethindrone—Convulsion—Fluorouracil—urinary bladder cancer	0.00056	0.00222	CcSEcCtD
Norethindrone—Thrombophlebitis—Doxorubicin—urinary bladder cancer	0.000559	0.00222	CcSEcCtD
Norethindrone—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—urinary bladder cancer	0.000556	0.00221	CcSEcCtD
Norethindrone—Gastrointestinal disorder—Thiotepa—urinary bladder cancer	0.000551	0.00219	CcSEcCtD
Norethindrone—Photosensitivity—Doxorubicin—urinary bladder cancer	0.000551	0.00219	CcSEcCtD
Norethindrone—Fatigue—Thiotepa—urinary bladder cancer	0.00055	0.00218	CcSEcCtD
Norethindrone—Renal impairment—Epirubicin—urinary bladder cancer	0.000549	0.00218	CcSEcCtD
Norethindrone—Purpura—Epirubicin—urinary bladder cancer	0.000542	0.00215	CcSEcCtD
Norethindrone—Anaphylactoid reaction—Epirubicin—urinary bladder cancer	0.00054	0.00214	CcSEcCtD
Norethindrone—Oedema—Gemcitabine—urinary bladder cancer	0.000537	0.00213	CcSEcCtD
Norethindrone—Anaphylactic shock—Gemcitabine—urinary bladder cancer	0.000537	0.00213	CcSEcCtD
Norethindrone—Convulsion—Cisplatin—urinary bladder cancer	0.000531	0.00211	CcSEcCtD
Norethindrone—Mood swings—Methotrexate—urinary bladder cancer	0.000529	0.0021	CcSEcCtD
Norethindrone—Anaphylactic shock—Fluorouracil—urinary bladder cancer	0.000528	0.00209	CcSEcCtD
Norethindrone—Oedema—Fluorouracil—urinary bladder cancer	0.000528	0.00209	CcSEcCtD
Norethindrone—Pain in extremity—Epirubicin—urinary bladder cancer	0.000523	0.00207	CcSEcCtD
Norethindrone—Gastrointestinal pain—Thiotepa—urinary bladder cancer	0.000522	0.00207	CcSEcCtD
Norethindrone—Skin disorder—Gemcitabine—urinary bladder cancer	0.000521	0.00207	CcSEcCtD
Norethindrone—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—urinary bladder cancer	0.000518	0.00206	CcSEcCtD
Norethindrone—Affect lability—Epirubicin—urinary bladder cancer	0.000514	0.00204	CcSEcCtD
Norethindrone—Migraine—Epirubicin—urinary bladder cancer	0.000514	0.00204	CcSEcCtD
Norethindrone—CYP3A4—female reproductive system—urinary bladder cancer	0.000512	0.0177	CbGeAlD
Norethindrone—Renal impairment—Doxorubicin—urinary bladder cancer	0.000508	0.00202	CcSEcCtD
Norethindrone—Urticaria—Thiotepa—urinary bladder cancer	0.000507	0.00201	CcSEcCtD
Norethindrone—Breast disorder—Methotrexate—urinary bladder cancer	0.000505	0.002	CcSEcCtD
Norethindrone—Abdominal pain—Thiotepa—urinary bladder cancer	0.000504	0.002	CcSEcCtD
Norethindrone—Purpura—Doxorubicin—urinary bladder cancer	0.000502	0.00199	CcSEcCtD
Norethindrone—Oedema—Cisplatin—urinary bladder cancer	0.0005	0.00198	CcSEcCtD
Norethindrone—Anaphylactic shock—Cisplatin—urinary bladder cancer	0.0005	0.00198	CcSEcCtD
Norethindrone—Anaphylactoid reaction—Doxorubicin—urinary bladder cancer	0.0005	0.00198	CcSEcCtD
Norethindrone—Mood swings—Epirubicin—urinary bladder cancer	0.000495	0.00196	CcSEcCtD
Norethindrone—ABCB1—epithelium—urinary bladder cancer	0.000488	0.0169	CbGeAlD
Norethindrone—Convulsion—Etoposide—urinary bladder cancer	0.000486	0.00193	CcSEcCtD
Norethindrone—Skin disorder—Cisplatin—urinary bladder cancer	0.000486	0.00193	CcSEcCtD
Norethindrone—Insomnia—Gemcitabine—urinary bladder cancer	0.000485	0.00193	CcSEcCtD
Norethindrone—Pain in extremity—Doxorubicin—urinary bladder cancer	0.000484	0.00192	CcSEcCtD
Norethindrone—Insomnia—Fluorouracil—urinary bladder cancer	0.000477	0.00189	CcSEcCtD
Norethindrone—Somnolence—Gemcitabine—urinary bladder cancer	0.000477	0.00189	CcSEcCtD
Norethindrone—Affect lability—Doxorubicin—urinary bladder cancer	0.000476	0.00189	CcSEcCtD
Norethindrone—Migraine—Doxorubicin—urinary bladder cancer	0.000476	0.00189	CcSEcCtD
Norethindrone—Unspecified disorder of skin and subcutaneous tissue—Etoposide—urinary bladder cancer	0.000475	0.00188	CcSEcCtD
Norethindrone—Breast disorder—Epirubicin—urinary bladder cancer	0.000472	0.00187	CcSEcCtD
Norethindrone—Hypersensitivity—Thiotepa—urinary bladder cancer	0.00047	0.00187	CcSEcCtD
Norethindrone—Somnolence—Fluorouracil—urinary bladder cancer	0.000469	0.00186	CcSEcCtD
Norethindrone—Dyspepsia—Fluorouracil—urinary bladder cancer	0.000464	0.00184	CcSEcCtD
Norethindrone—Gastrointestinal disorder—Gemcitabine—urinary bladder cancer	0.000463	0.00184	CcSEcCtD
Norethindrone—Fatigue—Gemcitabine—urinary bladder cancer	0.000463	0.00184	CcSEcCtD
Norethindrone—Anaphylactic shock—Etoposide—urinary bladder cancer	0.000458	0.00182	CcSEcCtD
Norethindrone—Mood swings—Doxorubicin—urinary bladder cancer	0.000458	0.00182	CcSEcCtD
Norethindrone—Asthenia—Thiotepa—urinary bladder cancer	0.000458	0.00182	CcSEcCtD
Norethindrone—Gastrointestinal disorder—Fluorouracil—urinary bladder cancer	0.000456	0.00181	CcSEcCtD
Norethindrone—Abdominal distension—Epirubicin—urinary bladder cancer	0.000455	0.0018	CcSEcCtD
Norethindrone—Drospirenone—PTGS2—urinary bladder cancer	0.000453	0.0326	CrCbGaD
Norethindrone—ABCB1—renal system—urinary bladder cancer	0.000453	0.0157	CbGeAlD
Norethindrone—Pruritus—Thiotepa—urinary bladder cancer	0.000451	0.00179	CcSEcCtD
Norethindrone—Skin disorder—Etoposide—urinary bladder cancer	0.000445	0.00177	CcSEcCtD
Norethindrone—ABCB1—urethra—urinary bladder cancer	0.000445	0.0154	CbGeAlD
Norethindrone—Photosensitivity reaction—Methotrexate—urinary bladder cancer	0.000441	0.00175	CcSEcCtD
Norethindrone—Breast disorder—Doxorubicin—urinary bladder cancer	0.000437	0.00173	CcSEcCtD
Norethindrone—Gastrointestinal disorder—Cisplatin—urinary bladder cancer	0.000432	0.00171	CcSEcCtD
Norethindrone—Drowsiness—Methotrexate—urinary bladder cancer	0.00043	0.00171	CcSEcCtD
Norethindrone—Depression—Methotrexate—urinary bladder cancer	0.000429	0.0017	CcSEcCtD
Norethindrone—Renal failure—Methotrexate—urinary bladder cancer	0.000423	0.00168	CcSEcCtD
Norethindrone—Dizziness—Thiotepa—urinary bladder cancer	0.000422	0.00167	CcSEcCtD
Norethindrone—Abdominal distension—Doxorubicin—urinary bladder cancer	0.000421	0.00167	CcSEcCtD
Norethindrone—Urticaria—Fluorouracil—urinary bladder cancer	0.000419	0.00166	CcSEcCtD
Norethindrone—Photosensitivity reaction—Epirubicin—urinary bladder cancer	0.000412	0.00164	CcSEcCtD
Norethindrone—Weight increased—Epirubicin—urinary bladder cancer	0.000411	0.00163	CcSEcCtD
Norethindrone—Somnolence—Etoposide—urinary bladder cancer	0.000407	0.00162	CcSEcCtD
Norethindrone—Hepatobiliary disease—Methotrexate—urinary bladder cancer	0.000407	0.00162	CcSEcCtD
Norethindrone—Vomiting—Thiotepa—urinary bladder cancer	0.000406	0.00161	CcSEcCtD
Norethindrone—Drowsiness—Epirubicin—urinary bladder cancer	0.000403	0.0016	CcSEcCtD
Norethindrone—Rash—Thiotepa—urinary bladder cancer	0.000402	0.0016	CcSEcCtD
Norethindrone—Dermatitis—Thiotepa—urinary bladder cancer	0.000402	0.00159	CcSEcCtD
Norethindrone—Headache—Thiotepa—urinary bladder cancer	0.0004	0.00159	CcSEcCtD
Norethindrone—Renal failure—Epirubicin—urinary bladder cancer	0.000396	0.00157	CcSEcCtD
Norethindrone—Gastrointestinal disorder—Etoposide—urinary bladder cancer	0.000396	0.00157	CcSEcCtD
Norethindrone—Fatigue—Etoposide—urinary bladder cancer	0.000395	0.00157	CcSEcCtD
Norethindrone—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.000389	0.00154	CcSEcCtD
Norethindrone—Haemoglobin—Methotrexate—urinary bladder cancer	0.000388	0.00154	CcSEcCtD
Norethindrone—Haemorrhage—Methotrexate—urinary bladder cancer	0.000386	0.00153	CcSEcCtD
Norethindrone—Hepatitis—Methotrexate—urinary bladder cancer	0.000386	0.00153	CcSEcCtD
Norethindrone—Asthenia—Gemcitabine—urinary bladder cancer	0.000385	0.00153	CcSEcCtD
Norethindrone—Photosensitivity reaction—Doxorubicin—urinary bladder cancer	0.000381	0.00151	CcSEcCtD
Norethindrone—Hepatobiliary disease—Epirubicin—urinary bladder cancer	0.000381	0.00151	CcSEcCtD
Norethindrone—Weight increased—Doxorubicin—urinary bladder cancer	0.00038	0.00151	CcSEcCtD
Norethindrone—Pruritus—Gemcitabine—urinary bladder cancer	0.00038	0.00151	CcSEcCtD
Norethindrone—Nausea—Thiotepa—urinary bladder cancer	0.000379	0.0015	CcSEcCtD
Norethindrone—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.000375	0.00149	CcSEcCtD
Norethindrone—Pruritus—Fluorouracil—urinary bladder cancer	0.000373	0.00148	CcSEcCtD
Norethindrone—Drowsiness—Doxorubicin—urinary bladder cancer	0.000373	0.00148	CcSEcCtD
Norethindrone—Hypersensitivity—Cisplatin—urinary bladder cancer	0.000369	0.00146	CcSEcCtD
Norethindrone—Renal failure—Doxorubicin—urinary bladder cancer	0.000366	0.00145	CcSEcCtD
Norethindrone—Erythema multiforme—Methotrexate—urinary bladder cancer	0.000365	0.00145	CcSEcCtD
Norethindrone—Urticaria—Etoposide—urinary bladder cancer	0.000364	0.00144	CcSEcCtD
Norethindrone—Haemoglobin—Epirubicin—urinary bladder cancer	0.000363	0.00144	CcSEcCtD
Norethindrone—ABCB1—female reproductive system—urinary bladder cancer	0.000363	0.0126	CbGeAlD
Norethindrone—Abdominal pain—Etoposide—urinary bladder cancer	0.000362	0.00144	CcSEcCtD
Norethindrone—Haemorrhage—Epirubicin—urinary bladder cancer	0.000362	0.00143	CcSEcCtD
Norethindrone—Hepatitis—Epirubicin—urinary bladder cancer	0.000362	0.00143	CcSEcCtD
Norethindrone—Asthenia—Cisplatin—urinary bladder cancer	0.000359	0.00142	CcSEcCtD
Norethindrone—Connective tissue disorder—Epirubicin—urinary bladder cancer	0.000355	0.00141	CcSEcCtD
Norethindrone—Hepatobiliary disease—Doxorubicin—urinary bladder cancer	0.000352	0.0014	CcSEcCtD
Norethindrone—Progesterone—ESR1—urinary bladder cancer	0.000349	0.0251	CrCbGaD
Norethindrone—Immune system disorder—Methotrexate—urinary bladder cancer	0.000349	0.00138	CcSEcCtD
Norethindrone—Dizziness—Fluorouracil—urinary bladder cancer	0.000349	0.00138	CcSEcCtD
Norethindrone—Erythema multiforme—Epirubicin—urinary bladder cancer	0.000342	0.00136	CcSEcCtD
Norethindrone—Alopecia—Methotrexate—urinary bladder cancer	0.000341	0.00135	CcSEcCtD
Norethindrone—Vomiting—Gemcitabine—urinary bladder cancer	0.000341	0.00135	CcSEcCtD
Norethindrone—Mental disorder—Methotrexate—urinary bladder cancer	0.000338	0.00134	CcSEcCtD
Norethindrone—Rash—Gemcitabine—urinary bladder cancer	0.000338	0.00134	CcSEcCtD
Norethindrone—Dermatitis—Gemcitabine—urinary bladder cancer	0.000338	0.00134	CcSEcCtD
Norethindrone—Hypersensitivity—Etoposide—urinary bladder cancer	0.000338	0.00134	CcSEcCtD
Norethindrone—Haemoglobin—Doxorubicin—urinary bladder cancer	0.000336	0.00133	CcSEcCtD
Norethindrone—Headache—Gemcitabine—urinary bladder cancer	0.000336	0.00133	CcSEcCtD
Norethindrone—Vomiting—Fluorouracil—urinary bladder cancer	0.000335	0.00133	CcSEcCtD
Norethindrone—Haemorrhage—Doxorubicin—urinary bladder cancer	0.000335	0.00133	CcSEcCtD
Norethindrone—Hepatitis—Doxorubicin—urinary bladder cancer	0.000335	0.00133	CcSEcCtD
Norethindrone—Rash—Fluorouracil—urinary bladder cancer	0.000333	0.00132	CcSEcCtD
Norethindrone—Dermatitis—Fluorouracil—urinary bladder cancer	0.000332	0.00132	CcSEcCtD
Norethindrone—Headache—Fluorouracil—urinary bladder cancer	0.000331	0.00131	CcSEcCtD
Norethindrone—Asthenia—Etoposide—urinary bladder cancer	0.000329	0.0013	CcSEcCtD
Norethindrone—Connective tissue disorder—Doxorubicin—urinary bladder cancer	0.000329	0.0013	CcSEcCtD
Norethindrone—ABCB1—vagina—urinary bladder cancer	0.000328	0.0114	CbGeAlD
Norethindrone—Immune system disorder—Epirubicin—urinary bladder cancer	0.000327	0.0013	CcSEcCtD
Norethindrone—Pruritus—Etoposide—urinary bladder cancer	0.000324	0.00129	CcSEcCtD
Norethindrone—Alopecia—Epirubicin—urinary bladder cancer	0.000319	0.00127	CcSEcCtD
Norethindrone—Nausea—Gemcitabine—urinary bladder cancer	0.000319	0.00126	CcSEcCtD
Norethindrone—Vomiting—Cisplatin—urinary bladder cancer	0.000318	0.00126	CcSEcCtD
Norethindrone—Mental disorder—Epirubicin—urinary bladder cancer	0.000317	0.00126	CcSEcCtD
Norethindrone—Erythema multiforme—Doxorubicin—urinary bladder cancer	0.000316	0.00126	CcSEcCtD
Norethindrone—Rash—Cisplatin—urinary bladder cancer	0.000315	0.00125	CcSEcCtD
Norethindrone—Dermatitis—Cisplatin—urinary bladder cancer	0.000315	0.00125	CcSEcCtD
Norethindrone—Nausea—Fluorouracil—urinary bladder cancer	0.000313	0.00124	CcSEcCtD
Norethindrone—Flatulence—Epirubicin—urinary bladder cancer	0.00031	0.00123	CcSEcCtD
Norethindrone—Tension—Epirubicin—urinary bladder cancer	0.000309	0.00123	CcSEcCtD
Norethindrone—Nervousness—Epirubicin—urinary bladder cancer	0.000306	0.00121	CcSEcCtD
Norethindrone—Dizziness—Etoposide—urinary bladder cancer	0.000303	0.0012	CcSEcCtD
Norethindrone—Immune system disorder—Doxorubicin—urinary bladder cancer	0.000302	0.0012	CcSEcCtD
Norethindrone—Nausea—Cisplatin—urinary bladder cancer	0.000297	0.00118	CcSEcCtD
Norethindrone—Alopecia—Doxorubicin—urinary bladder cancer	0.000296	0.00117	CcSEcCtD
Norethindrone—Mental disorder—Doxorubicin—urinary bladder cancer	0.000293	0.00116	CcSEcCtD
Norethindrone—Convulsion—Methotrexate—urinary bladder cancer	0.000291	0.00116	CcSEcCtD
Norethindrone—Vomiting—Etoposide—urinary bladder cancer	0.000291	0.00116	CcSEcCtD
Norethindrone—Rash—Etoposide—urinary bladder cancer	0.000289	0.00115	CcSEcCtD
Norethindrone—Dermatitis—Etoposide—urinary bladder cancer	0.000289	0.00115	CcSEcCtD
Norethindrone—Headache—Etoposide—urinary bladder cancer	0.000287	0.00114	CcSEcCtD
Norethindrone—Flatulence—Doxorubicin—urinary bladder cancer	0.000287	0.00114	CcSEcCtD
Norethindrone—Tension—Doxorubicin—urinary bladder cancer	0.000286	0.00113	CcSEcCtD
Norethindrone—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	0.000284	0.00113	CcSEcCtD
Norethindrone—Nervousness—Doxorubicin—urinary bladder cancer	0.000283	0.00112	CcSEcCtD
Norethindrone—Anaphylactic shock—Methotrexate—urinary bladder cancer	0.000274	0.00109	CcSEcCtD
Norethindrone—Convulsion—Epirubicin—urinary bladder cancer	0.000273	0.00108	CcSEcCtD
Norethindrone—Nausea—Etoposide—urinary bladder cancer	0.000272	0.00108	CcSEcCtD
Norethindrone—Skin disorder—Methotrexate—urinary bladder cancer	0.000267	0.00106	CcSEcCtD
Norethindrone—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	0.000266	0.00106	CcSEcCtD
Norethindrone—Anaphylactic shock—Epirubicin—urinary bladder cancer	0.000257	0.00102	CcSEcCtD
Norethindrone—Oedema—Epirubicin—urinary bladder cancer	0.000257	0.00102	CcSEcCtD
Norethindrone—Convulsion—Doxorubicin—urinary bladder cancer	0.000252	0.001	CcSEcCtD
Norethindrone—Skin disorder—Epirubicin—urinary bladder cancer	0.000249	0.00099	CcSEcCtD
Norethindrone—Insomnia—Methotrexate—urinary bladder cancer	0.000248	0.000985	CcSEcCtD
Norethindrone—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	0.000246	0.000977	CcSEcCtD
Norethindrone—Somnolence—Methotrexate—urinary bladder cancer	0.000244	0.000968	CcSEcCtD
Norethindrone—Dyspepsia—Methotrexate—urinary bladder cancer	0.000242	0.000959	CcSEcCtD
Norethindrone—Oedema—Doxorubicin—urinary bladder cancer	0.000238	0.000943	CcSEcCtD
Norethindrone—Anaphylactic shock—Doxorubicin—urinary bladder cancer	0.000238	0.000943	CcSEcCtD
Norethindrone—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	0.000237	0.00094	CcSEcCtD
Norethindrone—Fatigue—Methotrexate—urinary bladder cancer	0.000237	0.000939	CcSEcCtD
Norethindrone—Insomnia—Epirubicin—urinary bladder cancer	0.000232	0.000922	CcSEcCtD
Norethindrone—Skin disorder—Doxorubicin—urinary bladder cancer	0.000231	0.000916	CcSEcCtD
Norethindrone—Somnolence—Epirubicin—urinary bladder cancer	0.000228	0.000906	CcSEcCtD
Norethindrone—Dyspepsia—Epirubicin—urinary bladder cancer	0.000226	0.000897	CcSEcCtD
Norethindrone—Gastrointestinal pain—Methotrexate—urinary bladder cancer	0.000224	0.000891	CcSEcCtD
Norethindrone—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	0.000222	0.00088	CcSEcCtD
Norethindrone—Fatigue—Epirubicin—urinary bladder cancer	0.000221	0.000879	CcSEcCtD
Norethindrone—Urticaria—Methotrexate—urinary bladder cancer	0.000218	0.000865	CcSEcCtD
Norethindrone—Abdominal pain—Methotrexate—urinary bladder cancer	0.000217	0.000861	CcSEcCtD
Norethindrone—Insomnia—Doxorubicin—urinary bladder cancer	0.000215	0.000853	CcSEcCtD
Norethindrone—ABCB1—lymph node—urinary bladder cancer	0.000212	0.00735	CbGeAlD
Norethindrone—Somnolence—Doxorubicin—urinary bladder cancer	0.000211	0.000838	CcSEcCtD
Norethindrone—Gastrointestinal pain—Epirubicin—urinary bladder cancer	0.00021	0.000834	CcSEcCtD
Norethindrone—Dyspepsia—Doxorubicin—urinary bladder cancer	0.000209	0.00083	CcSEcCtD
Norethindrone—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	0.000205	0.000814	CcSEcCtD
Norethindrone—Fatigue—Doxorubicin—urinary bladder cancer	0.000205	0.000813	CcSEcCtD
Norethindrone—Urticaria—Epirubicin—urinary bladder cancer	0.000204	0.00081	CcSEcCtD
Norethindrone—Abdominal pain—Epirubicin—urinary bladder cancer	0.000203	0.000806	CcSEcCtD
Norethindrone—Hypersensitivity—Methotrexate—urinary bladder cancer	0.000202	0.000802	CcSEcCtD
Norethindrone—Asthenia—Methotrexate—urinary bladder cancer	0.000197	0.000781	CcSEcCtD
Norethindrone—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	0.000194	0.000771	CcSEcCtD
Norethindrone—Pruritus—Methotrexate—urinary bladder cancer	0.000194	0.000771	CcSEcCtD
Norethindrone—Hypersensitivity—Epirubicin—urinary bladder cancer	0.000189	0.000751	CcSEcCtD
Norethindrone—Urticaria—Doxorubicin—urinary bladder cancer	0.000189	0.000749	CcSEcCtD
Norethindrone—Abdominal pain—Doxorubicin—urinary bladder cancer	0.000188	0.000746	CcSEcCtD
Norethindrone—Asthenia—Epirubicin—urinary bladder cancer	0.000184	0.000731	CcSEcCtD
Norethindrone—Pruritus—Epirubicin—urinary bladder cancer	0.000182	0.000721	CcSEcCtD
Norethindrone—Dizziness—Methotrexate—urinary bladder cancer	0.000181	0.00072	CcSEcCtD
Norethindrone—Hypersensitivity—Doxorubicin—urinary bladder cancer	0.000175	0.000695	CcSEcCtD
Norethindrone—Vomiting—Methotrexate—urinary bladder cancer	0.000175	0.000693	CcSEcCtD
Norethindrone—Rash—Methotrexate—urinary bladder cancer	0.000173	0.000687	CcSEcCtD
Norethindrone—Dermatitis—Methotrexate—urinary bladder cancer	0.000173	0.000686	CcSEcCtD
Norethindrone—Headache—Methotrexate—urinary bladder cancer	0.000172	0.000682	CcSEcCtD
Norethindrone—Asthenia—Doxorubicin—urinary bladder cancer	0.000171	0.000677	CcSEcCtD
Norethindrone—Dizziness—Epirubicin—urinary bladder cancer	0.00017	0.000674	CcSEcCtD
Norethindrone—Pruritus—Doxorubicin—urinary bladder cancer	0.000168	0.000667	CcSEcCtD
Norethindrone—Vomiting—Epirubicin—urinary bladder cancer	0.000163	0.000648	CcSEcCtD
Norethindrone—Nausea—Methotrexate—urinary bladder cancer	0.000163	0.000647	CcSEcCtD
Norethindrone—Rash—Epirubicin—urinary bladder cancer	0.000162	0.000643	CcSEcCtD
Norethindrone—Dermatitis—Epirubicin—urinary bladder cancer	0.000162	0.000642	CcSEcCtD
Norethindrone—Headache—Epirubicin—urinary bladder cancer	0.000161	0.000639	CcSEcCtD
Norethindrone—Dizziness—Doxorubicin—urinary bladder cancer	0.000157	0.000624	CcSEcCtD
Norethindrone—Nausea—Epirubicin—urinary bladder cancer	0.000153	0.000605	CcSEcCtD
Norethindrone—Vomiting—Doxorubicin—urinary bladder cancer	0.000151	0.0006	CcSEcCtD
Norethindrone—Rash—Doxorubicin—urinary bladder cancer	0.00015	0.000595	CcSEcCtD
Norethindrone—Dermatitis—Doxorubicin—urinary bladder cancer	0.00015	0.000594	CcSEcCtD
Norethindrone—Headache—Doxorubicin—urinary bladder cancer	0.000149	0.000591	CcSEcCtD
Norethindrone—Nausea—Doxorubicin—urinary bladder cancer	0.000141	0.00056	CcSEcCtD
Norethindrone—CYP3A7—Metabolism—CYP4B1—urinary bladder cancer	9.8e-05	0.000935	CbGpPWpGaD
Norethindrone—ABCB1—Integrated Pancreatic Cancer Pathway—CCNE1—urinary bladder cancer	9.73e-05	0.000928	CbGpPWpGaD
Norethindrone—ALB—Folate Metabolism—TNF—urinary bladder cancer	9.6e-05	0.000916	CbGpPWpGaD
Norethindrone—ABCB1—Integrated Pancreatic Cancer Pathway—TYMS—urinary bladder cancer	9.56e-05	0.000912	CbGpPWpGaD
Norethindrone—PGR—Gene Expression—ESR2—urinary bladder cancer	9.42e-05	0.000899	CbGpPWpGaD
Norethindrone—ALB—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	9.32e-05	0.000889	CbGpPWpGaD
Norethindrone—CYP3A7—Metabolism—SLC19A1—urinary bladder cancer	9.26e-05	0.000883	CbGpPWpGaD
Norethindrone—CYP3A5—Metabolism—GSTZ1—urinary bladder cancer	9.07e-05	0.000866	CbGpPWpGaD
Norethindrone—CYP3A7—Metabolism—PRSS3—urinary bladder cancer	9.02e-05	0.00086	CbGpPWpGaD
Norethindrone—CYP3A5—Metabolism—GSTO2—urinary bladder cancer	8.6e-05	0.000821	CbGpPWpGaD
Norethindrone—CYP3A5—Metabolism—NAT1—urinary bladder cancer	8.6e-05	0.000821	CbGpPWpGaD
Norethindrone—ABCB1—Integrated Pancreatic Cancer Pathway—FAS—urinary bladder cancer	8.47e-05	0.000808	CbGpPWpGaD
Norethindrone—ALB—Folate Metabolism—TP53—urinary bladder cancer	8.46e-05	0.000807	CbGpPWpGaD
Norethindrone—ABCB1—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	8.17e-05	0.000779	CbGpPWpGaD
Norethindrone—CYP3A5—Metabolism—UGT2B7—urinary bladder cancer	7.87e-05	0.00075	CbGpPWpGaD
Norethindrone—ALB—Metabolism—GSTZ1—urinary bladder cancer	7.82e-05	0.000745	CbGpPWpGaD
Norethindrone—ALB—Selenium Micronutrient Network—TNF—urinary bladder cancer	7.63e-05	0.000727	CbGpPWpGaD
Norethindrone—ABCB1—Integrated Pancreatic Cancer Pathway—ATM—urinary bladder cancer	7.48e-05	0.000714	CbGpPWpGaD
Norethindrone—ABCB1—Integrated Pancreatic Cancer Pathway—CDK4—urinary bladder cancer	7.45e-05	0.000711	CbGpPWpGaD
Norethindrone—ABCB1—Integrated Pancreatic Cancer Pathway—ESR1—urinary bladder cancer	7.42e-05	0.000708	CbGpPWpGaD
Norethindrone—ALB—Metabolism—NAT1—urinary bladder cancer	7.41e-05	0.000707	CbGpPWpGaD
Norethindrone—ALB—Metabolism—GSTO2—urinary bladder cancer	7.41e-05	0.000707	CbGpPWpGaD
Norethindrone—ALB—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	7.29e-05	0.000695	CbGpPWpGaD
Norethindrone—ABCB1—Allograft Rejection—TNF—urinary bladder cancer	7.29e-05	0.000695	CbGpPWpGaD
Norethindrone—PGR—Gene Expression—NCOR1—urinary bladder cancer	7.28e-05	0.000694	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—RBX1—urinary bladder cancer	7.26e-05	0.000692	CbGpPWpGaD
Norethindrone—CYP3A7—Metabolism—TYMP—urinary bladder cancer	7.21e-05	0.000688	CbGpPWpGaD
Norethindrone—CYP3A5—Metabolism—CYP4B1—urinary bladder cancer	7.08e-05	0.000676	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—GSTZ1—urinary bladder cancer	7.02e-05	0.000669	CbGpPWpGaD
Norethindrone—CYP3A4—Biological oxidations—GSTP1—urinary bladder cancer	6.89e-05	0.000657	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—GSTZ1—urinary bladder cancer	6.85e-05	0.000653	CbGpPWpGaD
Norethindrone—PGR—Gene Expression—ERCC2—urinary bladder cancer	6.84e-05	0.000652	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—TSC1—urinary bladder cancer	6.82e-05	0.000651	CbGpPWpGaD
Norethindrone—CYP3A4—Metapathway biotransformation—GSTP1—urinary bladder cancer	6.79e-05	0.000648	CbGpPWpGaD
Norethindrone—ALB—Metabolism—UGT2B7—urinary bladder cancer	6.78e-05	0.000646	CbGpPWpGaD
Norethindrone—CYP3A5—Metabolism—SLC19A1—urinary bladder cancer	6.69e-05	0.000638	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—GSTO2—urinary bladder cancer	6.65e-05	0.000634	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—NAT1—urinary bladder cancer	6.65e-05	0.000634	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	6.54e-05	0.000624	CbGpPWpGaD
Norethindrone—ALB—Platelet activation, signaling and aggregation—IGF1—urinary bladder cancer	6.52e-05	0.000622	CbGpPWpGaD
Norethindrone—CYP3A7—Metabolism—NAT2—urinary bladder cancer	6.52e-05	0.000622	CbGpPWpGaD
Norethindrone—CYP3A5—Metabolism—PRSS3—urinary bladder cancer	6.52e-05	0.000622	CbGpPWpGaD
Norethindrone—ABCB1—Integrated Pancreatic Cancer Pathway—CREBBP—urinary bladder cancer	6.5e-05	0.00062	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—JAG1—urinary bladder cancer	6.5e-05	0.00062	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—GSTO2—urinary bladder cancer	6.49e-05	0.000619	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—NAT1—urinary bladder cancer	6.49e-05	0.000619	CbGpPWpGaD
Norethindrone—ABCB1—Integrated Pancreatic Cancer Pathway—IGF1—urinary bladder cancer	6.42e-05	0.000613	CbGpPWpGaD
Norethindrone—CYP3A4—Biological oxidations—GSTM1—urinary bladder cancer	6.33e-05	0.000604	CbGpPWpGaD
Norethindrone—ALB—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	6.3e-05	0.000601	CbGpPWpGaD
Norethindrone—CYP3A4—Metapathway biotransformation—GSTM1—urinary bladder cancer	6.24e-05	0.000595	CbGpPWpGaD
Norethindrone—PGR—Generic Transcription Pathway—MYC—urinary bladder cancer	6.17e-05	0.000589	CbGpPWpGaD
Norethindrone—ALB—Metabolism—CYP4B1—urinary bladder cancer	6.1e-05	0.000582	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—UGT2B7—urinary bladder cancer	6.08e-05	0.00058	CbGpPWpGaD
Norethindrone—ALB—Platelet activation, signaling and aggregation—RHOA—urinary bladder cancer	5.97e-05	0.00057	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—UGT2B7—urinary bladder cancer	5.94e-05	0.000566	CbGpPWpGaD
Norethindrone—ALB—Hemostasis—IFNA2—urinary bladder cancer	5.82e-05	0.000555	CbGpPWpGaD
Norethindrone—ALB—Metabolism—SLC19A1—urinary bladder cancer	5.76e-05	0.00055	CbGpPWpGaD
Norethindrone—PGR—Gene Expression—ESR1—urinary bladder cancer	5.71e-05	0.000545	CbGpPWpGaD
Norethindrone—CYP3A7—Metabolism—RRM2—urinary bladder cancer	5.63e-05	0.000537	CbGpPWpGaD
Norethindrone—ALB—Metabolism—PRSS3—urinary bladder cancer	5.61e-05	0.000536	CbGpPWpGaD
Norethindrone—ABCB1—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	5.52e-05	0.000526	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—CYP4B1—urinary bladder cancer	5.48e-05	0.000522	CbGpPWpGaD
Norethindrone—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—urinary bladder cancer	5.45e-05	0.000519	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—CYP4B1—urinary bladder cancer	5.35e-05	0.00051	CbGpPWpGaD
Norethindrone—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—urinary bladder cancer	5.33e-05	0.000508	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—S100B—urinary bladder cancer	5.26e-05	0.000502	CbGpPWpGaD
Norethindrone—PGR—Gene Expression—PPARG—urinary bladder cancer	5.21e-05	0.000497	CbGpPWpGaD
Norethindrone—CYP3A7—Metabolism—ENO2—urinary bladder cancer	5.21e-05	0.000497	CbGpPWpGaD
Norethindrone—CYP3A7—Metabolism—HPGDS—urinary bladder cancer	5.21e-05	0.000497	CbGpPWpGaD
Norethindrone—CYP3A5—Metabolism—TYMP—urinary bladder cancer	5.21e-05	0.000497	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—SLC19A1—urinary bladder cancer	5.17e-05	0.000493	CbGpPWpGaD
Norethindrone—CYP3A7—Metabolism—GSTT1—urinary bladder cancer	5.06e-05	0.000482	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—SLC19A1—urinary bladder cancer	5.05e-05	0.000482	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—PRSS3—urinary bladder cancer	5.04e-05	0.000481	CbGpPWpGaD
Norethindrone—ALB—Platelet activation, signaling and aggregation—IL2—urinary bladder cancer	5.01e-05	0.000478	CbGpPWpGaD
Norethindrone—PGR—Gene Expression—CREBBP—urinary bladder cancer	5.01e-05	0.000478	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—PRSS3—urinary bladder cancer	4.92e-05	0.000469	CbGpPWpGaD
Norethindrone—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—urinary bladder cancer	4.81e-05	0.000459	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—NCOR1—urinary bladder cancer	4.73e-05	0.000451	CbGpPWpGaD
Norethindrone—CYP3A5—Metabolism—NAT2—urinary bladder cancer	4.71e-05	0.00045	CbGpPWpGaD
Norethindrone—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1A—urinary bladder cancer	4.65e-05	0.000444	CbGpPWpGaD
Norethindrone—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—urinary bladder cancer	4.64e-05	0.000443	CbGpPWpGaD
Norethindrone—ALB—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	4.5e-05	0.000429	CbGpPWpGaD
Norethindrone—ALB—Metabolism—TYMP—urinary bladder cancer	4.49e-05	0.000428	CbGpPWpGaD
Norethindrone—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—urinary bladder cancer	4.43e-05	0.000422	CbGpPWpGaD
Norethindrone—ALB—Platelet activation, signaling and aggregation—SRC—urinary bladder cancer	4.37e-05	0.000417	CbGpPWpGaD
Norethindrone—ALB—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	4.31e-05	0.000411	CbGpPWpGaD
Norethindrone—ABCB1—Integrated Pancreatic Cancer Pathway—SRC—urinary bladder cancer	4.31e-05	0.000411	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—GSTZ1—urinary bladder cancer	4.22e-05	0.000402	CbGpPWpGaD
Norethindrone—CYP3A7—Metabolism—NQO1—urinary bladder cancer	4.2e-05	0.000401	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—TERT—urinary bladder cancer	4.17e-05	0.000398	CbGpPWpGaD
Norethindrone—ALB—Hemostasis—PLAU—urinary bladder cancer	4.13e-05	0.000394	CbGpPWpGaD
Norethindrone—CYP3A5—Metabolism—RRM2—urinary bladder cancer	4.07e-05	0.000388	CbGpPWpGaD
Norethindrone—ALB—Metabolism—NAT2—urinary bladder cancer	4.06e-05	0.000387	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	4.04e-05	0.000385	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—TYMP—urinary bladder cancer	4.03e-05	0.000384	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—GSTO2—urinary bladder cancer	4e-05	0.000381	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—NAT1—urinary bladder cancer	4e-05	0.000381	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—TYMP—urinary bladder cancer	3.93e-05	0.000375	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	3.87e-05	0.000369	CbGpPWpGaD
Norethindrone—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—urinary bladder cancer	3.86e-05	0.000368	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—FGFR3—urinary bladder cancer	3.83e-05	0.000365	CbGpPWpGaD
Norethindrone—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—urinary bladder cancer	3.77e-05	0.00036	CbGpPWpGaD
Norethindrone—CYP3A5—Metabolism—ENO2—urinary bladder cancer	3.77e-05	0.000359	CbGpPWpGaD
Norethindrone—CYP3A5—Metabolism—HPGDS—urinary bladder cancer	3.77e-05	0.000359	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—ESR1—urinary bladder cancer	3.72e-05	0.000354	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—UGT2B7—urinary bladder cancer	3.66e-05	0.000349	CbGpPWpGaD
Norethindrone—CYP3A5—Metabolism—GSTT1—urinary bladder cancer	3.65e-05	0.000349	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—NAT2—urinary bladder cancer	3.64e-05	0.000348	CbGpPWpGaD
Norethindrone—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—urinary bladder cancer	3.6e-05	0.000343	CbGpPWpGaD
Norethindrone—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—urinary bladder cancer	3.57e-05	0.00034	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—NAT2—urinary bladder cancer	3.56e-05	0.000339	CbGpPWpGaD
Norethindrone—CYP3A7—Metabolism—GSTP1—urinary bladder cancer	3.5e-05	0.000334	CbGpPWpGaD
Norethindrone—ALB—Metabolism—RRM2—urinary bladder cancer	3.5e-05	0.000334	CbGpPWpGaD
Norethindrone—ALB—Hemostasis—CREBBP—urinary bladder cancer	3.4e-05	0.000325	CbGpPWpGaD
Norethindrone—ALB—Hemostasis—IGF1—urinary bladder cancer	3.36e-05	0.000321	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—CYP4B1—urinary bladder cancer	3.29e-05	0.000314	CbGpPWpGaD
Norethindrone—CYP3A7—Metabolism—TYMS—urinary bladder cancer	3.26e-05	0.000311	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—CREBBP—urinary bladder cancer	3.26e-05	0.000311	CbGpPWpGaD
Norethindrone—ALB—Metabolism—HPGDS—urinary bladder cancer	3.25e-05	0.00031	CbGpPWpGaD
Norethindrone—ALB—Metabolism—ENO2—urinary bladder cancer	3.25e-05	0.00031	CbGpPWpGaD
Norethindrone—ALB—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	3.23e-05	0.000308	CbGpPWpGaD
Norethindrone—CYP3A7—Metabolism—NCOR1—urinary bladder cancer	3.22e-05	0.000307	CbGpPWpGaD
Norethindrone—CYP3A7—Metabolism—GSTM1—urinary bladder cancer	3.22e-05	0.000307	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—IGF1—urinary bladder cancer	3.22e-05	0.000307	CbGpPWpGaD
Norethindrone—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—urinary bladder cancer	3.17e-05	0.000302	CbGpPWpGaD
Norethindrone—ALB—Metabolism—GSTT1—urinary bladder cancer	3.15e-05	0.0003	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—RRM2—urinary bladder cancer	3.15e-05	0.0003	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—SLC19A1—urinary bladder cancer	3.11e-05	0.000297	CbGpPWpGaD
Norethindrone—ALB—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	3.1e-05	0.000296	CbGpPWpGaD
Norethindrone—CYP3A7—Metabolism—GPX1—urinary bladder cancer	3.08e-05	0.000294	CbGpPWpGaD
Norethindrone—ALB—Hemostasis—RHOA—urinary bladder cancer	3.08e-05	0.000294	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—RRM2—urinary bladder cancer	3.07e-05	0.000293	CbGpPWpGaD
Norethindrone—CYP3A5—Metabolism—NQO1—urinary bladder cancer	3.04e-05	0.00029	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—PRSS3—urinary bladder cancer	3.03e-05	0.000289	CbGpPWpGaD
Norethindrone—CYP3A7—Metabolism—ERCC2—urinary bladder cancer	3.03e-05	0.000289	CbGpPWpGaD
Norethindrone—PGR—Gene Expression—MYC—urinary bladder cancer	2.97e-05	0.000284	CbGpPWpGaD
Norethindrone—ALB—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	2.95e-05	0.000281	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—RHOA—urinary bladder cancer	2.95e-05	0.000281	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—ENO2—urinary bladder cancer	2.91e-05	0.000278	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—HPGDS—urinary bladder cancer	2.91e-05	0.000278	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	2.9e-05	0.000276	CbGpPWpGaD
Norethindrone—CYP3A7—Metabolism—MTHFR—urinary bladder cancer	2.85e-05	0.000271	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—ENO2—urinary bladder cancer	2.84e-05	0.000271	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—HPGDS—urinary bladder cancer	2.84e-05	0.000271	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—GSTT1—urinary bladder cancer	2.83e-05	0.00027	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	2.78e-05	0.000265	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—GSTT1—urinary bladder cancer	2.76e-05	0.000263	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—ERBB2—urinary bladder cancer	2.73e-05	0.00026	CbGpPWpGaD
Norethindrone—ALB—Metabolism—NQO1—urinary bladder cancer	2.62e-05	0.00025	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—CXCL8—urinary bladder cancer	2.59e-05	0.000247	CbGpPWpGaD
Norethindrone—ALB—Hemostasis—IL2—urinary bladder cancer	2.58e-05	0.000246	CbGpPWpGaD
Norethindrone—ABCB1—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	2.58e-05	0.000246	CbGpPWpGaD
Norethindrone—ALB—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	2.54e-05	0.000242	CbGpPWpGaD
Norethindrone—CYP3A5—Metabolism—GSTP1—urinary bladder cancer	2.53e-05	0.000242	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—IL2—urinary bladder cancer	2.47e-05	0.000236	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—TYMP—urinary bladder cancer	2.42e-05	0.000231	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—CCND1—urinary bladder cancer	2.41e-05	0.00023	CbGpPWpGaD
Norethindrone—CYP3A5—Metabolism—TYMS—urinary bladder cancer	2.36e-05	0.000225	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—NQO1—urinary bladder cancer	2.35e-05	0.000224	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—MMP9—urinary bladder cancer	2.34e-05	0.000223	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—CDKN1A—urinary bladder cancer	2.33e-05	0.000222	CbGpPWpGaD
Norethindrone—CYP3A5—Metabolism—GSTM1—urinary bladder cancer	2.33e-05	0.000222	CbGpPWpGaD
Norethindrone—CYP3A5—Metabolism—NCOR1—urinary bladder cancer	2.33e-05	0.000222	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—PTEN—urinary bladder cancer	2.33e-05	0.000222	CbGpPWpGaD
Norethindrone—ALB—Hemostasis—EP300—urinary bladder cancer	2.32e-05	0.000221	CbGpPWpGaD
Norethindrone—CYP3A7—Metabolism—PPARG—urinary bladder cancer	2.31e-05	0.00022	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—NQO1—urinary bladder cancer	2.29e-05	0.000219	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	2.28e-05	0.000217	CbGpPWpGaD
Norethindrone—ALB—Hemostasis—SRC—urinary bladder cancer	2.25e-05	0.000215	CbGpPWpGaD
Norethindrone—CYP3A5—Metabolism—GPX1—urinary bladder cancer	2.23e-05	0.000213	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—EP300—urinary bladder cancer	2.22e-05	0.000212	CbGpPWpGaD
Norethindrone—CYP3A7—Metabolism—CREBBP—urinary bladder cancer	2.22e-05	0.000211	CbGpPWpGaD
Norethindrone—ALB—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	2.21e-05	0.000211	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—NAT2—urinary bladder cancer	2.19e-05	0.000209	CbGpPWpGaD
Norethindrone—CYP3A5—Metabolism—ERCC2—urinary bladder cancer	2.19e-05	0.000209	CbGpPWpGaD
Norethindrone—ALB—Metabolism—GSTP1—urinary bladder cancer	2.18e-05	0.000208	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—SRC—urinary bladder cancer	2.16e-05	0.000206	CbGpPWpGaD
Norethindrone—ALB—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	2.11e-05	0.000201	CbGpPWpGaD
Norethindrone—CYP3A5—Metabolism—MTHFR—urinary bladder cancer	2.06e-05	0.000196	CbGpPWpGaD
Norethindrone—ALB—Metabolism—TYMS—urinary bladder cancer	2.03e-05	0.000193	CbGpPWpGaD
Norethindrone—ALB—Metabolism—NCOR1—urinary bladder cancer	2e-05	0.000191	CbGpPWpGaD
Norethindrone—ALB—Metabolism—GSTM1—urinary bladder cancer	2e-05	0.000191	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.99e-05	0.00019	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—GSTP1—urinary bladder cancer	1.96e-05	0.000187	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—MYC—urinary bladder cancer	1.93e-05	0.000184	CbGpPWpGaD
Norethindrone—ALB—Metabolism—GPX1—urinary bladder cancer	1.92e-05	0.000183	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—GSTP1—urinary bladder cancer	1.91e-05	0.000182	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.89e-05	0.000181	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—RRM2—urinary bladder cancer	1.89e-05	0.00018	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—EGFR—urinary bladder cancer	1.89e-05	0.00018	CbGpPWpGaD
Norethindrone—ALB—Metabolism—ERCC2—urinary bladder cancer	1.89e-05	0.00018	CbGpPWpGaD
Norethindrone—ALB—Hemostasis—KRAS—urinary bladder cancer	1.87e-05	0.000178	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—TYMS—urinary bladder cancer	1.82e-05	0.000174	CbGpPWpGaD
Norethindrone—CYP3A7—Metabolism—PTGS2—urinary bladder cancer	1.82e-05	0.000173	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—GSTM1—urinary bladder cancer	1.8e-05	0.000172	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—NCOR1—urinary bladder cancer	1.8e-05	0.000172	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—KRAS—urinary bladder cancer	1.79e-05	0.00017	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—TYMS—urinary bladder cancer	1.78e-05	0.00017	CbGpPWpGaD
Norethindrone—ALB—Metabolism—MTHFR—urinary bladder cancer	1.77e-05	0.000169	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—NCOR1—urinary bladder cancer	1.76e-05	0.000168	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—GSTM1—urinary bladder cancer	1.76e-05	0.000168	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—ENO2—urinary bladder cancer	1.75e-05	0.000167	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	1.75e-05	0.000167	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—GPX1—urinary bladder cancer	1.72e-05	0.000164	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	1.7e-05	0.000162	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—ERCC2—urinary bladder cancer	1.69e-05	0.000161	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—GPX1—urinary bladder cancer	1.68e-05	0.00016	CbGpPWpGaD
Norethindrone—CYP3A5—Metabolism—PPARG—urinary bladder cancer	1.67e-05	0.000159	CbGpPWpGaD
Norethindrone—ALB—Hemostasis—TP53—urinary bladder cancer	1.66e-05	0.000158	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—ERCC2—urinary bladder cancer	1.65e-05	0.000158	CbGpPWpGaD
Norethindrone—CYP3A5—Metabolism—CREBBP—urinary bladder cancer	1.6e-05	0.000153	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—MTHFR—urinary bladder cancer	1.59e-05	0.000152	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—TP53—urinary bladder cancer	1.59e-05	0.000151	CbGpPWpGaD
Norethindrone—ALB—Hemostasis—HRAS—urinary bladder cancer	1.59e-05	0.000151	CbGpPWpGaD
Norethindrone—CYP3A7—Metabolism—PTEN—urinary bladder cancer	1.58e-05	0.000151	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—MTHFR—urinary bladder cancer	1.55e-05	0.000148	CbGpPWpGaD
Norethindrone—PGR—Signaling Pathways—HRAS—urinary bladder cancer	1.52e-05	0.000145	CbGpPWpGaD
Norethindrone—CYP3A7—Metabolism—EP300—urinary bladder cancer	1.51e-05	0.000144	CbGpPWpGaD
Norethindrone—ALB—Metabolism—PPARG—urinary bladder cancer	1.44e-05	0.000137	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—NQO1—urinary bladder cancer	1.41e-05	0.000135	CbGpPWpGaD
Norethindrone—ALB—Metabolism—CREBBP—urinary bladder cancer	1.38e-05	0.000132	CbGpPWpGaD
Norethindrone—CYP3A5—Metabolism—PTGS2—urinary bladder cancer	1.31e-05	0.000125	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—PPARG—urinary bladder cancer	1.29e-05	0.000123	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—PPARG—urinary bladder cancer	1.26e-05	0.00012	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—CREBBP—urinary bladder cancer	1.24e-05	0.000118	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—CREBBP—urinary bladder cancer	1.21e-05	0.000115	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	1.18e-05	0.000112	CbGpPWpGaD
Norethindrone—CYP3A5—Metabolism—PTEN—urinary bladder cancer	1.14e-05	0.000109	CbGpPWpGaD
Norethindrone—ALB—Metabolism—PTGS2—urinary bladder cancer	1.13e-05	0.000108	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—TYMS—urinary bladder cancer	1.09e-05	0.000104	CbGpPWpGaD
Norethindrone—CYP3A5—Metabolism—EP300—urinary bladder cancer	1.09e-05	0.000104	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	1.08e-05	0.000103	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	1.08e-05	0.000103	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—GPX1—urinary bladder cancer	1.04e-05	9.89e-05	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	1.02e-05	9.71e-05	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—PTGS2—urinary bladder cancer	1.01e-05	9.68e-05	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—PTGS2—urinary bladder cancer	9.9e-06	9.45e-05	CbGpPWpGaD
Norethindrone—ALB—Metabolism—PTEN—urinary bladder cancer	9.86e-06	9.4e-05	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	9.57e-06	9.12e-05	CbGpPWpGaD
Norethindrone—ALB—Metabolism—EP300—urinary bladder cancer	9.4e-06	8.97e-05	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—PTEN—urinary bladder cancer	8.85e-06	8.44e-05	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—PTEN—urinary bladder cancer	8.64e-06	8.24e-05	CbGpPWpGaD
Norethindrone—CYP2C19—Metabolism—EP300—urinary bladder cancer	8.44e-06	8.05e-05	CbGpPWpGaD
Norethindrone—ABCB1—Metabolism—EP300—urinary bladder cancer	8.24e-06	7.86e-05	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—PPARG—urinary bladder cancer	7.76e-06	7.4e-05	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	7.45e-06	7.11e-05	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	6.1e-06	5.82e-05	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—PTEN—urinary bladder cancer	5.32e-06	5.08e-05	CbGpPWpGaD
Norethindrone—CYP3A4—Metabolism—EP300—urinary bladder cancer	5.07e-06	4.84e-05	CbGpPWpGaD
